Alimera Sciences (NASDAQ:ALIM) pared an earlier drop to 6% after it said it filed a lawsuit against ANI Pharmaceuticals (ANIP) to compel the company to close its acquisition of Alimera.

In May, Alimera Sciences reported a whopping 70% year-on-year increase in net revenue to $23 million on the back of a 23% growth in the global end user demand. The biopharmaceuticals sales company ...

NASDAQ ALIM opened at $5.54 on Wednesday. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The stock has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta ...

Ani Pharmaceuticals ( (ANIP) ) has released its Q3 earnings. Here is a breakdown of the information Ani Pharmaceuticals presented to its ...

For Q3, investors will be centered on the Alimera (ALIM) acquisition following its delayed closure, and the firm’s main spotlight during the earnings call will be on the FDA warning letter ...

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is ...

We also put a new, more efficient and effective capital structure in place and completed the acquisition of Alimera, which is highly synergistic to our Rare Disease business. We believe our proven ...